Business Context and Reporting Period
This Form 8-K, filed on August 5, 2016, reports on transactions by Sunshine Heart, Inc. (the "Company"). The filing details the acquisition of the Aquadex FlexFlow business from Gambro UF Solutions, Inc. (a subsidiary of Baxter International Inc.) and the restructuring of the Company's debt facilities with Silicon Valley Bank.
Key Financial Metrics and Transaction Details
Acquisition Consideration
- Cash Payment: $4.0 million paid to the Seller.
- Equity Payment: 1,000,000 shares of Company common stock issued to the Seller.
- Contingent Consideration: If the Company sells the acquired assets for more than $4.0 million within three years, the Seller receives 40% of the excess amount.
Debt and Liquidity
- Debt Repayment: The Company repaid approximately $6.0 million to settle its prior loan agreement (including ~$5.5 million principal, ~$3,200 interest, $400,000 final payment, and ~$109,000 prepayment premium).
- New Debt Facility: A new $5.0 million credit facility was established, consisting of a $4.0 million term loan and a $1.0 million revolving line of credit.
- Interest Rates: Term loan accrues at Prime + 2.50%; Revolving line accrues at Prime + 1.75% or Prime + 1.0% depending on liquidity metrics.
- Liquidity Covenants: The Company must maintain net liquidity equal to at least four times its monthly cash burn amount. The filing notes the Company does not currently meet this covenant.
Material Changes Versus Prior Period
- Asset Base: The Company acquired the Aquadex FlexFlow product line, a medical device for treating heart failure and fluid overload.
- Capital Structure: The Company issued 1,000,000 new shares of common stock (unregistered) and replaced its existing debt facility with a new, larger facility.
- Intellectual Property: The Company obtained a worldwide license for patents related to the acquired product, with rights reverting to the Seller in the event of bankruptcy or cessation of the business.
Guidance, Outlook, and Risks
- Financial Covenants: The new loan agreement includes strict financial covenants regarding net liquidity relative to monthly cash burn. The Company currently does not meet these requirements, creating a risk of default if not remedied.
- Equity Repurchase Option: If the Company's stock ceases to trade on the Nasdaq Capital Market, the Seller has the option to require the Company to repurchase the 1,000,000 shares at fair market value.
- Preemptive Rights: The Seller has the right to participate pro rata in any subsequent equity financing on or before July 31, 2017.
- Restrictions: The new loan agreement restricts the Company from declaring dividends, incurring additional indebtedness, or engaging in mergers/acquisitions without consent.
- Unusual Items: The filing does not provide specific revenue, profit, or cash flow figures for the reporting period, as this is a current report on specific events rather than a periodic financial statement.
Investor Verification Checklist
- Verify the Company's current net liquidity and monthly cash burn to assess compliance with the new loan covenants.
- Confirm the fair market value of the 1,000,000 shares issued to the Seller and the potential dilution impact.
- Review the transition services and commercial manufacturing agreements to understand ongoing dependencies on the Seller.
- Monitor the Company's ability to raise capital or improve liquidity to avoid triggering the Seller's stock repurchase option or loan default.
- Check for the upcoming filing of pro forma financial information (due within 71 days) to understand the combined financial position.